References
[1] Tan Yue, GE Ningning, Peng Jing, et al. Signal mining and evaluation of adverse drug events in children with tocilizumab and infliximab [J]. Chin J Clinical Pharmacology, 2024, 40 (05): 732-736.
[2] Albahdal S A, Alotaibi M A, Alanazi A M, et al. Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study [J]. Cost-effectiveness and Resource Allocation: C/E, 2024, 22 (1): 14.
[3] Zhang Xue, Li Dake. Rheumatic immune-related adverse reactions and treatment of immune checkpoint inhibitors [J]. Cancer Prevention and Treatment Research, 2020, 47 (11): 894-899.
[4] Zhang Weiqin, Zhao Huawei, Wang Zhenzhen, et al. Treatment of a child with refractory anti-NMDAR encephalitis with tocili-zumab: case report and literature review [J/OL]. Chinese Modern Applied Pharmacy, 1-5 [2024-03-27].
[5] Liu Xiyu, Sun Mengyao, Ren Na, et al. The role of T cell-associated signaling pathways in the pathogenesis of Takayasu's arteritis [J]. Chin J Lab Diagnostics, 2023, 27 (04): 501-505.
[6] Han R. Diagnosis and treatment of a case of giant cell arteritis with paroxysmal visual impairment [J]. Chinese Journal of Practical Rural Doctor, 2022, 29 (01): 71-74.
[7] Zhu L S. The mechanism of Porphyromonas gingivalis affecting the immune response of macrophages and the screening of anti-bacterial Chinese medicine monomers [D]. Shanghai University of Traditional Chinese Medicine, 2021.
[8] Xi X Q. Giant cell arteritis and polymyalgia rheumatica [J]. Chinese Journal of Practical Rural Doctor, 2020, 27 (02): 9-11. (in Chinese)
[9] Tang Yanni, Yuan Yiming, Zhang Yingting. Giant cell arteritis with fever as the initial symptom: a case report [J]. Chin J Clinol (Electronic Edition), 2019, 13 (10): 798-800.
[10] Wang Yu, Zhang Yun, Wang Dongmei, et al. Clinical characteristics of giant cell arteritis with positive pathology and its correlation with pathological results [J]. Basic Medicine & Clinic, 2019, 39 (05): 731-734.
[11] Wu Xiao, Zheng Yuehong. Progress in diagnosis and treatment of giant cell arteritis causing intermittent claudication of the lower limbs [J]. Chin J Multiple Organ Diseases, 2018, 17 (08): 617-620.
[12] Chen Sufen, Zhang Meichen, Dong Zhao, et al. Clinical and prognostic analysis of giant cell arteritis patients presenting with pain. Chinese Journal of Pain Medicine, 2018, 24 (08): 610-614.
[13] Yin Yue, Zhang Yun, Zeng Xuejun. Giant cell arteritis and fever of unknown origin in the elderly [J]. Basic Medicine & Clinic, 2018, 38 (08): 1168-1172.
[14] GAO Kaiyan, Yuan Fenghong, Xu Wei, et al. PET-CT diagnosis of giant cell arteritis: report of 4 cases and review of literature [J]. Chongqing Med, 2017, 46 (33): 4673-4675+4679.
[15] Chen Xiaoming. The first drug Actemra(tocilizumab) approved by FDA for the treatment of giant cell arteritis [J]. Journal of Guangdong Pharmaceutical University, 2017, 33 (03): 289.
[16] Tong Chunmei. A case of posterior scleral inflammatory giant cell arteritis [J]. Chinese Journal of PLA Medicine, 2017, 29 (02): 2+117.
[17] Huang Huifang, Huo Lijuan, Guo Junzhi, et al. Giant cell arteritis diagnosed by positron emission computed tomography/CT: a case report with abdominal pain and fatigue [J]. Chin Materia Medica & Clinic, 2017, 17 (01): 151-152.
[18] Yuan Xiang, Li Xiaomei. Application of imaging techniques in the diagnosis of giant cell arteritis [J]. Chin J Clinical Immunology and Allergy, 2016, 10 (02): 170-174.
[19] Wang Limin, Yu Jing, Gao Mingli. Giant cell arteritis with fever as the first manifestation: a case report and literature analysis [J]. Shanxi Med J, 2016, 45 (09): 1083-1087.
[20] Wang Youying. Curative effect of giant cell arteritis and polymyalgia rheumatica [J]. Digest of World Latest Medical Information, 2015, 15 (A2): 90-91.
[21] T. Klink, J. Geiger, M. Both, et al. Giant cell arteritis: accuracy of MRI in the initial diagnosis of superficial cranial arteries: results from a multi-center trial [J]. International Journal of Medical Radiology, 2015, 38 (01): 78.